Omnicell (NASDAQ:OMCL) had its price target raised by analysts at Oppenheimer to $86.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 23.16% from the stock’s previous close.
A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $80.00 target price (up from $70.00) on shares of Omnicell in a report on Thursday. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 22nd. Zacks Investment Research restated a “strong-buy” rating and set a $78.00 target price on shares of Omnicell in a report on Wednesday, November 14th. Wells Fargo & Co boosted their target price on shares of Omnicell from $59.00 to $61.00 and gave the stock a “market perform” rating in a report on Monday, October 29th. Finally, MED boosted their target price on shares of Omnicell from $59.00 to $71.00 and gave the stock an “in-line” rating in a report on Monday, October 22nd. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $73.75.
Shares of OMCL opened at $69.83 on Friday. The firm has a market cap of $2.80 billion, a P/E ratio of 387.94, a PEG ratio of 4.22 and a beta of 0.99. Omnicell has a 1-year low of $39.75 and a 1-year high of $79.48. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.32 and a current ratio of 1.78.
In other Omnicell news, Director James T. Judson sold 5,000 shares of Omnicell stock in a transaction on Monday, October 1st. The shares were sold at an average price of $71.18, for a total transaction of $355,900.00. Following the completion of the transaction, the director now directly owns 29,952 shares of the company’s stock, valued at $2,131,983.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Dan S. Johnston sold 6,250 shares of Omnicell stock in a transaction on Monday, October 15th. The stock was sold at an average price of $63.47, for a total transaction of $396,687.50. Following the transaction, the executive vice president now directly owns 35,996 shares of the company’s stock, valued at $2,284,666.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 19,267 shares of company stock valued at $1,309,116. Company insiders own 3.71% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can bought a new position in Omnicell during the second quarter worth $102,000. Stone Ridge Asset Management LLC bought a new position in Omnicell during the third quarter worth $202,000. Everence Capital Management Inc. bought a new position in Omnicell during the third quarter worth $204,000. Ibex Investors LLC bought a new position in Omnicell during the third quarter worth $209,000. Finally, Evanston Investments Inc. dba Evanston Advisors bought a new position in Omnicell during the third quarter worth $216,000.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.